DOP2019000312A - Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas - Google Patents
Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosasInfo
- Publication number
- DOP2019000312A DOP2019000312A DO2019000312A DO2019000312A DOP2019000312A DO P2019000312 A DOP2019000312 A DO P2019000312A DO 2019000312 A DO2019000312 A DO 2019000312A DO 2019000312 A DO2019000312 A DO 2019000312A DO P2019000312 A DOP2019000312 A DO P2019000312A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- mitoocetoscines
- mitochondries
- cancer cells
- therapeutic agents
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/14—Libraries containing macromolecular compounds and not covered by groups C40B40/06 - C40B40/12
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Computing Systems (AREA)
- Bioinformatics & Computational Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Indole Compounds (AREA)
Abstract
La presente descripción se refiere a compuestos que se enlazan a por lo menos una de ACAT1/2 y OXCT1/2 e inhiben la producción mitocondrial de ATP, referidos en este documento como mitocetoscinas. Se dan a conocer métodos de prospección de compuestos por la inhibición mitocondrial y propiedades anticancerosas. También se describen métodos para usar mitocetoscinas para prevenir o tratar cáncer, infecciones bacterianas y levadura patógena, así como también métodos para usar mitocetoscinas para proporcionar beneficios anti-envejecimiento. También se dan a conocer compuestos de mitocetoscina específicos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762524829P | 2017-06-26 | 2017-06-26 | |
| PCT/US2018/039354 WO2019005698A1 (en) | 2017-06-26 | 2018-06-25 | MITOCETOSCINES: MITOCHONDRIAL THERAPEUTIC AGENTS TARGETING THE METABOLISM OF KETONES IN CANCER CELLS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2019000312A true DOP2019000312A (es) | 2020-03-15 |
Family
ID=64742979
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2019000312A DOP2019000312A (es) | 2017-06-26 | 2019-12-19 | Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas |
| DO2022000142A DOP2022000142A (es) | 2017-06-26 | 2022-07-06 | Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2022000142A DOP2022000142A (es) | 2017-06-26 | 2022-07-06 | Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11667639B2 (es) |
| EP (1) | EP3644988B1 (es) |
| JP (1) | JP7397672B2 (es) |
| KR (2) | KR102646172B1 (es) |
| CN (1) | CN110913854B (es) |
| AU (2) | AU2018292283B2 (es) |
| CA (1) | CA3064452A1 (es) |
| CL (1) | CL2019003708A1 (es) |
| CO (1) | CO2019014259A2 (es) |
| CR (1) | CR20200033A (es) |
| CU (1) | CU20190106A7 (es) |
| DO (2) | DOP2019000312A (es) |
| EC (1) | ECSP20001729A (es) |
| IL (2) | IL292109B2 (es) |
| MX (1) | MX2019014806A (es) |
| PE (2) | PE20242070A1 (es) |
| PH (1) | PH12019502892A1 (es) |
| RU (1) | RU2020102908A (es) |
| SG (1) | SG11201913134UA (es) |
| WO (1) | WO2019005698A1 (es) |
| ZA (2) | ZA201907831B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2020102908A (ru) * | 2017-06-26 | 2021-07-27 | Лунелла Байотек, Инк. | Митокетосцины: митохондриальная терапия, нацеленная на кетоновый метаболизм в раковых клетках |
| CA3078791A1 (en) | 2017-10-11 | 2019-04-18 | Lunella Biotech, Inc. | Anti-mitochondrial inhibitors for oncogenic ras and myc |
| JP2021501774A (ja) * | 2017-11-03 | 2021-01-21 | バイオイミクス・アクチボラグＢｉｏｉｍｉｃｓ ＡＢ | 抗感染症複素環式化合物及びその使用 |
| EP3810284A4 (en) | 2018-06-01 | 2022-06-15 | Lunella Biotech, Inc. | BIOMARKERS AND THERAPEUTICS IN RESISTANCE TO ENDOCRINE THERAPY |
| CU24717B1 (es) | 2018-10-02 | 2024-08-15 | Lunella Biotech Inc | Derivados de azitromicina y roxitromicina como fármacos senolíticos |
| EP3976197B1 (en) | 2019-05-24 | 2025-07-16 | Lunella Biotech, Inc. | Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3517067A (en) | 1964-02-11 | 1970-06-23 | Eastman Kodak Co | Syntheses of quaternary phosphonium salts |
| EP0310361A3 (en) | 1987-09-30 | 1989-05-24 | Beckman Instruments, Inc. | Tridentate conjugate and method of use thereof |
| SI9011409A (en) | 1990-07-18 | 1995-10-31 | Pliva Pharm & Chem Works | O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them |
| FR2674522B1 (fr) | 1991-03-26 | 1993-07-16 | Lipha | Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant. |
| EP0656422B1 (en) | 1993-11-05 | 2000-04-26 | Amersham Pharmacia Biotech UK Limited | Chloramphenicol acetyl transferase (CAT) assay |
| WO1995015770A1 (en) | 1993-12-09 | 1995-06-15 | Neorx Corporation | Pretargeting methods and compounds |
| US5441939A (en) | 1994-03-04 | 1995-08-15 | Pfizer Inc. | 3"-desmethoxy derivatives of erythromycin and azithromycin |
| KR970702725A (ko) | 1994-04-26 | 1997-06-10 | 노부히로 나리따 | 비소세포 폐암 치료용 의약 조성물(Medicinal Composition as a Remedy for Nonsmall Cell Lung Cancer) |
| CA2219277A1 (en) | 1995-05-03 | 1996-11-07 | Pfizer Limited | Novel tetracycline derivatives |
| NZ505352A (en) | 1997-11-25 | 2002-12-20 | Univ Otago | Mitochondrially targeted antioxidants |
| PT941998E (pt) | 1998-03-03 | 2004-12-31 | Pfizer Prod Inc | Antibioticos macrolidos do tipo 3,6-cetal |
| AUPP437698A0 (en) | 1998-06-30 | 1998-07-23 | Baumgart, Karl | Methods for treatment of coronary, carotid and other vascular disease |
| US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US7485298B2 (en) | 2002-05-23 | 2009-02-03 | Michael Powell | Diagnosis and treatment of human dormancy-related sequellae |
| DK1592457T3 (da) | 2003-01-27 | 2012-10-22 | Endocyte Inc | Folat-vinblastin-konjugat som lægemiddel |
| TWI324600B (en) | 2003-07-07 | 2010-05-11 | Kowa Co | 2,4-bis (trifluoroethoxy) pyridine compound and drug containing the compound |
| US20070105937A1 (en) * | 2003-12-22 | 2007-05-10 | Miguel Pappolla | Indole-3-propionamide and derivatives thereof |
| JP2007523912A (ja) | 2004-02-26 | 2007-08-23 | アドバンスト アキュラー システムズ リミテッド | 眼病変治療用へパリン |
| US20060083727A1 (en) | 2004-07-15 | 2006-04-20 | Nanobac Pharmaceuticals, Inc. | Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation |
| TW200616604A (en) | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
| JP5065910B2 (ja) | 2005-01-14 | 2012-11-07 | グラクソ グループ リミテッド | ビオチンおよび光親和性基を含む、マクロライド標的同定用のマクロライド化合物 |
| CA2615374A1 (en) | 2005-07-18 | 2007-01-25 | Ernest Kun Kun | Treatment of cancer |
| US20080045589A1 (en) | 2006-05-26 | 2008-02-21 | Susan Kelley | Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer |
| WO2007143212A1 (en) | 2006-06-02 | 2007-12-13 | Ariad Gene Therapeutics, Inc. | Capecitabine combination therapy |
| WO2007147023A1 (en) | 2006-06-14 | 2007-12-21 | Bristol-Myers Squibb Company | An assay for measuring acyltransferase activity |
| CA2674238A1 (en) | 2006-10-30 | 2008-05-08 | Southern Research Institute | Targeting nbs1-atm interaction to sensitize cancer cells to radiotherapy and chemotherapy |
| EP3470071A1 (en) | 2006-12-14 | 2019-04-17 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| US8075902B2 (en) | 2007-01-03 | 2011-12-13 | Michael Powell | Diagnosis and treatment of cancer related to human dormancy |
| WO2009015214A2 (en) | 2007-07-24 | 2009-01-29 | Wayne State University | Nanoparticles for imaging and treating chlamydial infection |
| WO2009038656A1 (en) | 2007-09-17 | 2009-03-26 | Kosta Steliou | Mitochondria-targeting antioxidant therapeutics |
| US20100285001A1 (en) | 2007-10-02 | 2010-11-11 | University Of Rochester | Method and Compositions Related to Synergistic Responses to Oncogenic Mutations |
| CA2756820A1 (en) | 2009-04-17 | 2010-10-21 | Colby Pharmaceutical Company | Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses |
| EA201101639A1 (ru) | 2009-05-20 | 2012-06-29 | Юниверсите Де Женев | Ингибиторы митохондриальной активности клеток, инициирующих рак, и их применение |
| HRP20210537T1 (hr) | 2009-12-04 | 2021-05-14 | Oncoimmune Inc. | Upotreba inhibitora faktora induciranog hipoksijom |
| US8673587B2 (en) | 2010-05-04 | 2014-03-18 | Trustees Of Dartmouth College | Methods for identifying allosteric and other novel acyl-coenzyme A:cholesterol acyltransferase inhibitors |
| US20140322705A1 (en) * | 2010-08-20 | 2014-10-30 | Thomas Jefferson University | Cancer diagnostic and cancer therapeutic |
| US20120141467A1 (en) | 2010-12-03 | 2012-06-07 | Schneider Daniel J | Ascorbic acid to treat chronic obstructive lung diseases and non-Hodgkin's lymphoma |
| US20130172430A1 (en) | 2010-12-10 | 2013-07-04 | Michael P. Lisanti | Prognosis and treatment of breast cancer |
| BR112013033239A2 (pt) | 2011-06-22 | 2016-09-06 | Vyome Biosciences | pró-farmácos de conjugado baseado em atifungicos e antibacterianos |
| ES2627120T3 (es) | 2011-07-08 | 2017-07-26 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicamento para el tratamiento del cáncer de hígado |
| US9801922B2 (en) | 2011-08-03 | 2017-10-31 | University Of Iowa Research Foundation | Compositions and methods of treating cancer |
| WO2013024467A2 (en) | 2011-08-18 | 2013-02-21 | Ecole Polytechnique Federale De Lausanne (Epfl) | Mitochondrial ribosomal proteins as aging regulators |
| BR112014005268A2 (pt) * | 2011-09-09 | 2017-03-28 | Univ New York | compostos de amido como moduladores de ror t e usos dos mesmos |
| WO2013040206A1 (en) | 2011-09-14 | 2013-03-21 | Lewis Thomas J | Novel formulations comprising macrolide and tetracycline and their uses |
| EP2819993B1 (en) | 2012-03-01 | 2020-09-02 | University Of Cincinnati | Ros-activated compounds as selective anti-cancer therapeutics |
| US9526795B2 (en) | 2012-08-28 | 2016-12-27 | Annam Biosciences, Llc | N-BOC-dendrimers and their conjugates |
| WO2014036654A1 (en) | 2012-09-06 | 2014-03-13 | Mcmaster University | Compounds and methods for selectively targeting cancer stem cells |
| US20140106004A1 (en) | 2012-10-12 | 2014-04-17 | Bing Lou Wong | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
| US9636329B2 (en) | 2012-11-06 | 2017-05-02 | Northwestern University | Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors |
| US9937161B2 (en) | 2013-03-06 | 2018-04-10 | The General Hospital Corporation | Combinatorial compositions and methods for treatment of melanoma |
| US8728546B1 (en) * | 2013-03-15 | 2014-05-20 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer, cardiovascular diseases and inflammation |
| US10004809B2 (en) | 2013-07-01 | 2018-06-26 | University Of Georgia Research Foundation Inc. | Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy |
| US20150231069A1 (en) | 2014-02-20 | 2015-08-20 | Pankaj Modi | Oral formulations of chemotherapeutic agents |
| US20170224730A1 (en) | 2014-06-10 | 2017-08-10 | Institute For Myeloma & Bone Cancer Research | Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid |
| GB201414806D0 (en) | 2014-08-20 | 2014-10-01 | Ucl Business Plc | Cyclosporin conjugates |
| US10413558B2 (en) | 2014-10-17 | 2019-09-17 | Targeted Therapies Research And Consulting Center Sprl | Multi-ingredient pharmaceutical composition for use in cancer therapy |
| JP6439931B2 (ja) | 2015-02-26 | 2018-12-19 | 大日本印刷株式会社 | 吸着搬送装置および吸着搬送方法 |
| CA2997671A1 (en) | 2015-10-06 | 2017-04-13 | Redhill Biopharma Ltd. | Combination therapies for treating cancer |
| JP2019528689A (ja) | 2016-08-11 | 2019-10-17 | ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ | 免疫調節化合物 |
| WO2018136617A2 (en) | 2017-01-18 | 2018-07-26 | Evelo Biosciences, Inc. | Methods of treating cancer |
| WO2018136598A1 (en) | 2017-01-18 | 2018-07-26 | Evelo Biosciences, Inc. | Methods of treating cancer |
| US11197872B2 (en) | 2017-04-21 | 2021-12-14 | Lunella Biotech, Inc. | Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs) |
| CA3060509A1 (en) | 2017-04-21 | 2018-10-25 | Federica Sotgia | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
| WO2018202910A1 (en) | 2017-05-05 | 2018-11-08 | Fondazione Istituto Italiano Di Tecnologia | Combination of antibiotic and bcl-2 inhibitor and uses thereof |
| KR20200010343A (ko) | 2017-05-19 | 2020-01-30 | 루넬라 바이오테크 인코포레이티드 | 안티미토신: 암 줄기 세포를 근절하기 위한 미토콘드리아 생물발생의 표적화 억제제 |
| US12006553B2 (en) * | 2017-05-19 | 2024-06-11 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
| WO2018218242A1 (en) | 2017-05-26 | 2018-11-29 | Epicentrx, Inc. | Methods and compositions for combination therapy |
| RU2020102908A (ru) * | 2017-06-26 | 2021-07-27 | Лунелла Байотек, Инк. | Митокетосцины: митохондриальная терапия, нацеленная на кетоновый метаболизм в раковых клетках |
-
2018
- 2018-06-25 RU RU2020102908A patent/RU2020102908A/ru unknown
- 2018-06-25 PE PE2024001838A patent/PE20242070A1/es unknown
- 2018-06-25 MX MX2019014806A patent/MX2019014806A/es unknown
- 2018-06-25 PE PE2019002554A patent/PE20200295A1/es unknown
- 2018-06-25 CA CA3064452A patent/CA3064452A1/en active Pending
- 2018-06-25 AU AU2018292283A patent/AU2018292283B2/en active Active
- 2018-06-25 CR CR20200033A patent/CR20200033A/es unknown
- 2018-06-25 KR KR1020207001405A patent/KR102646172B1/ko active Active
- 2018-06-25 EP EP18822701.1A patent/EP3644988B1/en active Active
- 2018-06-25 CN CN201880042546.XA patent/CN110913854B/zh active Active
- 2018-06-25 SG SG11201913134UA patent/SG11201913134UA/en unknown
- 2018-06-25 WO PCT/US2018/039354 patent/WO2019005698A1/en not_active Ceased
- 2018-06-25 IL IL292109A patent/IL292109B2/en unknown
- 2018-06-25 CU CU2019000106A patent/CU20190106A7/es unknown
- 2018-06-25 JP JP2019570935A patent/JP7397672B2/ja active Active
- 2018-06-25 KR KR1020247007593A patent/KR102854338B1/ko active Active
- 2018-06-25 US US16/626,426 patent/US11667639B2/en active Active
-
2019
- 2019-11-20 IL IL270774A patent/IL270774A/en unknown
- 2019-11-26 ZA ZA2019/07831A patent/ZA201907831B/en unknown
- 2019-12-17 CO CONC2019/0014259A patent/CO2019014259A2/es unknown
- 2019-12-17 CL CL2019003708A patent/CL2019003708A1/es unknown
- 2019-12-19 DO DO2019000312A patent/DOP2019000312A/es unknown
- 2019-12-20 PH PH12019502892A patent/PH12019502892A1/en unknown
-
2020
- 2020-01-10 EC ECSENADI20201729A patent/ECSP20001729A/es unknown
- 2020-02-27 US US16/803,628 patent/US11667640B2/en active Active
- 2020-10-23 AU AU2020257159A patent/AU2020257159B2/en active Active
-
2021
- 2021-03-24 ZA ZA2021/01954A patent/ZA202101954B/en unknown
-
2022
- 2022-07-06 DO DO2022000142A patent/DOP2022000142A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2022000142A (es) | Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas | |
| DOP2022000164A (es) | Mitorriboscinas: compuestos terapéuticos basados en mitocondrias que fijan como objetivo células cancerosas, bacterias y levaduras patógenas | |
| MX2019005737A (es) | Composicion farmaceutica para prevenir o tratar el cancer de cerebro que incluye polimorfocristalino de hexaoxido de tetraarsenico y metodo para preparar el mismo. | |
| CL2018000429A1 (es) | Moduladores de la expresión de kras | |
| UY37145A (es) | Ligandos de direccionamiento | |
| MX2020004211A (es) | Mitoflavoscinas: la fijacion como objetivo de enzimas que contienen flavina elimina celulas madre cancerosas (cscs) al inhibir la respiracion mitocondrial. | |
| CO2018013557A2 (es) | Composiciones que comprenden cepas bacterianas | |
| CL2018003213A1 (es) | Inhibidores enzimáticos. | |
| BR112016012870A2 (pt) | ?métodos e composições para melhorar a produção de alface | |
| MX2016009898A (es) | Tratamientos para acne resistente. | |
| BR112016003127A2 (pt) | composições e métodos para modular rna | |
| DOP2019000019A (es) | Metodos para tratar el cancer de prostata | |
| BR112017021173A2 (pt) | benefícios de produtividade de planta por compostos microbianos | |
| BR112018074304A2 (pt) | composições de nanopartículas, kit e método para tratar um indivíduo com câncer resistente a fármacos | |
| BR112018017077A2 (pt) | terapias de combinação para tratamento de atrofia muscular espinhal | |
| CL2021001246A1 (es) | Moduladores de expresión irf5. | |
| MX2019002673A (es) | Composiciones y metodos para tratar demencia. | |
| UY38472A (es) | Moduladores de la expresión de foxp3 | |
| BR112018068097A2 (pt) | filtro solar físico consistindo de hidroxiapatita substituída em uma matriz orgânica | |
| MX2019010298A (es) | Resistencia a septoria en apio. | |
| BR112018009954A2 (pt) | materiais e métodos para o tratamento de miopatias baseadas em titinas e outras titinopatias |